Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.

Repeated intranasal ketamine for treatment-resistant depression – the way to go? Results from a pilot randomised controlled trial

Abstract

Background Ketamine research in depression has mostly used intravenous, weight-based approaches, which are difficult to translate clinically. Intranasal (IN) ketamine is a promising alternative but no controlled data has been published on the feasibility, safety and potential efficacy of repeated IN ketamine treatments. Methods This randomised, double-blind, placebo-controlled pilot study compared a 4-week course of eight treatments of 100 mg ketamine or 4.5 mg midazolam. Each treatment was given as 10 separate IN sprays, self-administered 5 min apart. The study was stopped early due to poor tolerability after five treatment-resistant depressed participants were included. Feasibility, safety (acute and cumulative), cognitive and efficacy outcomes were assessed. Plasma ketamine and norketamine concentrations were assayed after the first treatment. Results Significant acute cardiovascular, psychotomimetic and neurological side effects occurred at doses 45 min) due to acute side effects. No hepatic, cognitive or urinary changes were observed after the treatment course in either group. There was an approximately two-fold variation in ketamine and norketamine plasma concentrations between ketamine participants. At course end, one participant had remitted in each of the ketamine and midazolam groups. Conclusions IN ketamine, with the drug formulation and delivery device used, was not a useful treatment approach in this study. Absorption was variable between individuals and acute to…

Overview

Integrity signals

Registry

Crossref · 10.1177/0269881118760660

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 33 references

Research works printed but not linked: 4

  1. Daly E, 2016, 71st Society of Biological Psychiatry annual meeting
  2. Kushwaha SKS, 2011, J Appl Pharm Sci, 1, 21
  3. Sackeim HA, 2001, J Clin Psychiatry, 62, 10
  4. Sos P, 2013, Neuroendocrinology Letters, 34, 287

Cited by

See all 85

Metadata

Authors
Gálvez, V., Li, A., Huggins, C., Glue, P., Martin, D., Somogyi, A. A., Alonzo, A., Rodgers, A., Mitchell, P. B., & Loo, C. K.
Affiliations
  • Black Dog Institute (AU)
  • UNSW Sydney (AU)
  • University of Otago (NZ)
  • The University of Adelaide (AU)
  • The University of Sydney (AU)
Corresponding author
Loo, Colleen K
Venue
Journal of Psychopharmacology
Published
2018-03-15
Volume
32
Issue
4
Pages
397-407
ISSN
  • 0269-8811 (ISSN-L)
  • 1461-7285
OpenAlex
W2792882327
Cited by
85
References
33
Citations by year
2026: 3 · 2025: 13 · 2024: 5 · 2023: 13 · 2022: 13 · 2021: 13 · 2020: 13 · 2019: 7 · 2018: 5
FWCI
6.16
Type
journal article
Language
en
Open access
closed
Licence
journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
Locations
  • Journal of Psychopharmacology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
  • Life Sciences › Neuroscience › Neurology › Transcranial Magnetic Stimulation Studies
Keywords
intranasal ketamine, treatment-resistant depression, self-administration, tolerability, psychotomimetic side effects, drug absorption variability, cognitive effects
MeSH terms
Administration, Intranasal, Adult, Analgesics, Antidepressive Agents, Double-Blind Method, Female, Humans, Ketamine, Male, Midazolam, Middle Aged, Pilot Projects, Treatment Outcome, Depressive Disorder, Treatment-Resistant, Administration, Intravenous

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Repeated intranasal ketamine for treatment-resistant depression – the way to go? Results from a pilot randomised controlled trial. https://app.cochat.ai/papers/10.1177/0269881118760660
The paper
Gálvez, V., Li, A., Huggins, C., Glue, P., Martin, D., Somogyi, A. A., Alonzo, A., Rodgers, A., Mitchell, P. B., & Loo, C. K. (2018). Repeated intranasal ketamine for treatment-resistant depression – the way to go? Results from a pilot randomised controlled trial. Journal of Psychopharmacology. https://doi.org/10.1177/0269881118760660

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.